These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19135756)

  • 1. Cost-effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature.
    Neyt M; Van Brabandt H; Devriese S; De Laet C
    Health Policy; 2009 Jul; 91(2):107-20. PubMed ID: 19135756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
    Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
    Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting stents: a systematic review and economic evaluation.
    Hill RA; Boland A; Dickson R; Dündar Y; Haycox A; McLeod C; Mujica Mota R; Walley T; Bagust A
    Health Technol Assess; 2007 Nov; 11(46):iii, xi-221. PubMed ID: 17999841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of drug-eluting stents in acute myocardial infarction patients in Germany: results from administrative data using a propensity score-matching approach.
    Bäumler M; Stargardt T; Schreyögg J; Busse R
    Appl Health Econ Health Policy; 2012 Jul; 10(4):235-48. PubMed ID: 22574616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario.
    Goeree R; Bowen JM; Blackhouse G; Lazzam C; Cohen E; Chiu M; Hopkins R; Tarride JE; Tu JV
    Int J Technol Assess Health Care; 2009 Apr; 25(2):196-207. PubMed ID: 19331710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
    Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, humanistic, and economic outcomes between drug-eluting stent (DES) and bare metal stent (BMS): 18-month follow-up study.
    Lee VW; Cheng FW; Choi AY; Fong ST; Yu CM; Yan BP
    J Med Econ; 2017 Mar; 20(3):239-245. PubMed ID: 27737596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for the treatment of multivessel coronary artery disease in the drug-eluting stent era.
    Ariyaratne TV; Yap CH; Ademi Z; Rosenfeldt F; Duffy SJ; Billah B; Reid CM
    Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):261-270. PubMed ID: 29474722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of drug-eluting stents: a systematic literature review and model-based cost-utility analysis.
    Kuukasjärvi P; Räsänen P; Malmivaara A; Aronen P; Sintonen H
    Int J Technol Assess Health Care; 2007; 23(4):473-9. PubMed ID: 17937836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study.
    Stella SF; Gehling Bertoldi E; Polanczyk CA
    Med Decis Making; 2016 Nov; 36(8):1034-42. PubMed ID: 26964876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice.
    Schafer PE; Sacrinty MT; Cohen DJ; Kutcher MA; Gandhi SK; Santos RM; Little WC; Applegate RJ
    Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):408-15. PubMed ID: 21693724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Potential impact of drug-eluting stents in Sicily: results from a multicenter survey and cost-benefit analysis of drug-eluting stents versus bare metal stents].
    Gulizia M; Martelli E; Tamburino C; Tolaro S; Frasheri A; Giambanco F; Grassi R; Fiscella A; Milazzo D
    Ital Heart J Suppl; 2004 Aug; 5(8):630-8. PubMed ID: 15554018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada.
    Brophy JM; Erickson LJ
    Int J Technol Assess Health Care; 2005; 21(3):326-33. PubMed ID: 16110712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation.
    Auer J; Leitner A; Berent R; Lamm G; Lassnig E; Krennmair G
    Atherosclerosis; 2010 Jun; 210(2):503-9. PubMed ID: 20060973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.
    Goswami NJ; Gaffigan M; Berrio G; Plessa AL; Pfeiffer AM; Markwell SJ; Mishkel GJ
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):93-100. PubMed ID: 19787803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Cost of Drug-Eluting Stents versus Bare Metal Stents in the Treatment of Critical Limb Ischemia in the United States.
    Locham SS; Paracha N; Dakour-Aridi H; Nejim B; Rizwan M; Malas MB
    Ann Vasc Surg; 2019 Feb; 55():55-62.e2. PubMed ID: 30092444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET).
    Kaiser C; Brunner-La Rocca HP; Buser PT; Bonetti PO; Osswald S; Linka A; Bernheim A; Zutter A; Zellweger M; Grize L; Pfisterer ME;
    Lancet; 2005 Sep 10-16; 366(9489):921-9. PubMed ID: 16154019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.